Laurion Capital Management LP bought a new stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 87,103 shares of the biotechnology company’s stock, valued at approximately $2,757,000. Laurion Capital Management LP owned about 0.11% of Heron Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Aperio Group LLC raised its stake in shares of Heron Therapeutics by 14.4% during the second quarter. Aperio Group LLC now owns 11,261 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 1,416 shares in the last quarter. Wells Fargo & Company MN raised its position in Heron Therapeutics by 339.1% in the second quarter. Wells Fargo & Company MN now owns 265,847 shares of the biotechnology company’s stock worth $10,329,000 after acquiring an additional 205,302 shares in the last quarter. First Trust Advisors LP bought a new stake in Heron Therapeutics in the second quarter worth about $5,624,000. Jennison Associates LLC bought a new stake in Heron Therapeutics in the second quarter worth about $8,741,000. Finally, Alps Advisors Inc. raised its position in Heron Therapeutics by 20.5% in the second quarter. Alps Advisors Inc. now owns 103,723 shares of the biotechnology company’s stock worth $4,030,000 after acquiring an additional 17,646 shares in the last quarter.
HRTX has been the topic of several research reports. Cantor Fitzgerald set a $50.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 30th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “buy” rating and set a $34.00 price target on the stock in a research report on Thursday, October 11th. Stifel Nicolaus initiated coverage on shares of Heron Therapeutics in a research report on Thursday, September 13th. They issued a “buy” rating and a $55.00 price target on the stock. ValuEngine cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 4th. Finally, BidaskClub cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and a consensus price target of $52.09.
In related news, VP Kimberly Manhard sold 6,000 shares of Heron Therapeutics stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $32.07, for a total value of $192,420.00. Following the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at approximately $192,420. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin C. Tang sold 2,695,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. Insiders sold a total of 2,701,494 shares of company stock worth $96,553,796 in the last three months. 16.20% of the stock is currently owned by company insiders.
Shares of Heron Therapeutics stock opened at $26.55 on Friday. Heron Therapeutics Inc has a 52 week low of $15.00 and a 52 week high of $42.90.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.05). The company had revenue of $19.79 million during the quarter, compared to analysts’ expectations of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company’s revenue for the quarter was up 130.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.77) EPS. As a group, equities analysts expect that Heron Therapeutics Inc will post -2.34 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/12/08/laurion-capital-management-lp-takes-position-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Story: What is a bull market?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.